ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

CMS Advisors Express Low Confidence In Low-Dose CT Screening for Lung Cancer

May 9, 2014

New Mexico, Missouri, Columbia Next for Review As comprehensive Centers; UCLA Decision In October

September 17, 1976

Without Advance Directives, Families Prolong Treatment

April 27, 2001

Cervix Moves Significantly During Radiation for Cancer

February 27, 2009

Also Von Eschenbach role in industry program raises new concerns of conflict of interest.

November 23, 2005

Nobel Laureate Gilman Prepares to Leave The Texas Cancer Agency—Can it Survive?

September 28, 2012